Growth hormone (somatotropin) in the human body is responsible for the correct and timely growth and development of muscle and bone tissue. The most active secretion of the hormone is observed in childhood, then in adolescence and during puberty. Moreover, the older a person gets, the less somatotropin there is.
In adulthood, if a person has no health problems, there is no need for a large amount of this hormone. But only if the person is not involved in sports. In bodybuilding and other sports fields, the properties of somatotropin are highly valued. Many drugs are produced with an active substance that mimics the action of this hormone. Jintropin (Somatropin) 10 IU Gene Science Pharmaceuticals is one such drug.
Main positive effects of Jintropin (Somatropin) 10 IU Gene Science Pharmaceuticals
The first property of somatotropin is anabolic. This means that it causes active muscle growth. The increase in mass takes place organically and gradually. During one month you can gain up to 5 kg. In addition, the drug has an anti-catabolic effect, i.e. it prevents muscle breakdown. The muscles are hard and strong, dry.
The second property is fat burning. Somatotropin significantly reduces subcutaneous fat and helps to lose weight. This makes the relief more expressive, because the layer of fat that hides it disappears. During the fat burning process, energy is released.
The third property is to strengthen bones and connective tissue. The drug has a beneficial effect on the condition of joints and tendons, reducing the risk of injury during training.
Somatotropin also accelerates the regeneration of tissues, including the skin. Thus, it has a rejuvenating effect and accelerates the recovery process after injuries.
The main advantages of the drug:
- rare side effects;
- quickly noticeable result;
- no effect on libido and sexual function;
- no need to undergo PCT after the course.
It makes sense not to use Jintropin (Somatropin) 10 IU Gene Science Pharmaceuticals in all sports. For example, in weightlifting, where an athlete’s endurance and strength indicators are important, it is not used because it cannot affect performance. On the contrary, with an increase in the level of somatotropin, the fatigue threshold decreases. Therefore, it is often recommended to take it before bedtime.
Negative effects when taking growth hormone are rare. The drug is well absorbed and is suitable for both men and women. But in some cases, it can cause side effects. They are associated with excessive dosage or individual sensitivity to the hormone. Main side effects:
- carpal tunnel syndrome (pinching of a nerve by muscles, tendons or bones in the wrist);
- increased blood sugar;
- oedema, as the drug has the property of retaining fluid in cells;
- high blood pressure.
Somatotropin may also suppress the functioning of the thyroid gland, so people with thyroid problems should take the hormone with caution.
Recommendations for taking the hormone
You can start taking the hormone after consulting a doctor and ruling out contraindications. These include neoplasms, age under 21 years, pregnancy and lactation.
The drug is taken in 6-week courses. The time frame may vary depending on the results the athlete wishes to achieve. The same applies to the dosage: it is selected individually for each person to avoid overdosage and to achieve the best result without side effects.
List of references
- Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LF, Lombardi G. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. European Journal of Endocrinology. 2008;159(6):389-397.
- Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(6):1587-1609.
- Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Hormone Research in Paediatrics. 2016;86(6):361-397.
- Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, Crowe BJ, Ross JL, Cassorla FG, Blum WF, Cutler GB Jr, Baron J. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Endocrinology & Metabolism. 2004;89(7):3140-3148.
- Saenger P, Attie KM, DiMartino-Nardi J; HGH Study Group. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. Journal of Clinical Endocrinology & Metabolism. 2007;92(8):2938-2945.